The Novo Nordisk Inc. (NNI) Investigator Sponsored Studies (ISS) Program will accept protocols within our current areas of interest (AOI) as noted below. This is a competitive process. Incomplete submissions or protocols that are not within the scope of these AOIs/have low relevance to the thereaputic area may be rejected without further review. Submissions will be reviewed by the Novo Nordisk teams on both the US (NNI) and Global level. Decisions will be made based on scientific merit and strategic fit. Please review the submission requirements and abide by the timelines as outlined below.  The program requests that investigators specify how they will support enrollment of diverse populations in the study.

Please note that all new clinical ISS applications requesting semaglutide (injectables and oral formulation) are currently on pause and not being accepted.

Please note that all new clinical ISS applications requesting semaglutide (injectables and oral formulation) are currently on pause and not being accepted.

Peripheral artery disease (PAD) and long-term outcomes:

  • 6-min walk test
  • Claudication 
  • Major Adverse Limb Events (MALD)


Studies investigating:

  • Time in range (TIR)
  • Digital health and TIR
  • Impact of early tight glycemic control
  • Disease modification in Type 2 diabetes T2D (e.g., defining, implementing etc.)
  • Transition from living with pre-diabetes to (T2D) 
  • Major adverse cardiovascular events (MACE)


Subpopulations including but not limited to:

  • Type 1 diabetes
  • Adolescents
  • Ethnic/minority populations
  • History of Gestational diabetes mellitus
  • Hospitalized patients
  • Elderly/geriatric

  • Studies that overlap with completed, ongoing or planned research
  • Weight as the primary outcome

  • Protocol
  • Detailed line-item budget
  • Principal Investigator CV
  • Active medical license (e.g., if requesting study drug)
  • Conflict of Interest form

October 1st 2024

December 2024

March 1st 2025

May 2025